Outlook Therapeutics, Inc. 41ON.F Stock
Outlook Therapeutics, Inc. Price Chart
Outlook Therapeutics, Inc. 41ON.F Financial and Trading Overview
| Outlook Therapeutics, Inc. stock price | 0.29 EUR |
| Previous Close | 1.52 EUR |
| Open | 1.6 EUR |
| Bid | 1.6 EUR x N/A |
| Ask | 1.65 EUR x N/A |
| Day's Range | 1.6 - 1.6 EUR |
| 52 Week Range | 0.8 - 1.84 EUR |
| Volume | 944 EUR |
| Avg. Volume | 121 EUR |
| Market Cap | 426.32M EUR |
| Beta (5Y Monthly) | 0.62183 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7 EUR |
41ON.F Valuation Measures
| Enterprise Value | 378.34M EUR |
| Trailing P/E | N/A |
| Forward P/E | -6.9565215 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 39.02439 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -7.083 |
Trading Information
Outlook Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.62183 |
| 52-Week Change | -2.40% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.84 EUR |
| 52 Week Low | 0.8 EUR |
| 50-Day Moving Average | 1.13 EUR |
| 200-Day Moving Average | 1.08 EUR |
41ON.F Share Statistics
| Avg. Volume (3 month) | 121 EUR |
| Avg. Daily Volume (10-Days) | 190 EUR |
| Shares Outstanding | 256.67M |
| Float | 124.54M |
| Short Ratio | N/A |
| % Held by Insiders | 60.70% |
| % Held by Institutions | 10.76% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | September 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -54.98% |
| Return on Equity (ttm) | -246.29% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -42330856 EUR |
| EBITDA | -53412928 EUR |
| Net Income Avi to Common (ttm) | -57201784 EUR |
| Diluted EPS (ttm) | -0.21 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 43.63M EUR |
| Total Cash Per Share (mrq) | 0.17 EUR |
| Total Debt (mrq) | 31.84M EUR |
| Total Debt/Equity (mrq) | 303.57 EUR |
| Current Ratio (mrq) | 1.219 |
| Book Value Per Share (mrq) | 0.041 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -48365792 EUR |
| Levered Free Cash Flow (ttm) | -27853590 EUR |
Profile of Outlook Therapeutics, Inc.
| Country | Germany |
| State | NJ |
| City | Iselin |
| Address | Building F |
| ZIP | 08852 |
| Phone | 609 619 3990 |
| Website | https://www.outlooktherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 17 |
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Q&A For Outlook Therapeutics, Inc. Stock
What is a current 41ON.F stock price?
Outlook Therapeutics, Inc. 41ON.F stock price today per share is 0.29 EUR.
How to purchase Outlook Therapeutics, Inc. stock?
You can buy 41ON.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Outlook Therapeutics, Inc.?
The stock symbol or ticker of Outlook Therapeutics, Inc. is 41ON.F.
Which industry does the Outlook Therapeutics, Inc. company belong to?
The Outlook Therapeutics, Inc. industry is Biotechnology.
How many shares does Outlook Therapeutics, Inc. have in circulation?
The max supply of Outlook Therapeutics, Inc. shares is 25.34M.
What is Outlook Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Outlook Therapeutics, Inc. PE Ratio is 0.00000000 now.
What was Outlook Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Outlook Therapeutics, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Outlook Therapeutics, Inc. company belong to?
The Outlook Therapeutics, Inc. sector is Healthcare.